KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Questions topics:
› Opinion on abatacept failing to achieve its primary endpoint in its Phase III LN trial
› Views on the Phase III safety data for abatacept in LN
› Expectations regarding abatacept’s future development in lupus
› Opinion on ustekinumab’s ability to achieve partial improvements using SLEDAI-2K Responder Index-50
› Views on ustekinumab’s Phase III trial design
› Views on the absence of safety endpoints in the Phase III ustekinumab trial in SLE
› Perception of etanercept’s efficacy in discoid lupus erythematosus
› Opinion on etanercept’s safety data from the Phase II TARGET-DLE trial
Scope
› The insight briefing is based on Sociable Pharma’s analysis of primary research with our Lupus key opinion leaders (KOLs)
› In total, we conducted interviews with 10 KOLs:
– 5 Europe-based & 5 N. America-based
– Interviews performed during Aug 2018
> KOL data is analyzed to produce:
– Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma's analysts
Key Highlights
While most KOLs agreed that abatacept’s future in LN is uncertain, half of the KOLs highlighted that the drug has potential in lupus arthritis
Most KOLs highlighted that SLEDAI-2K Responder Index-50 data supports ustekinumab use in SLE
While most KOLs flagged that etanercept may exacerbate lupus features, half of the KOLs highlighted that etanercept has potential in lupus
Reasons to Buy
Combines Qualitative & semi-quantitative insight from key opinion leaders on Pipeline Therapy Data Presented at EULAR 2018
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
BMS
Pfizer
Merck
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.